pharmacodynamics
Download
Skip this Video
Download Presentation
Pharmacodynamics

Loading in 2 Seconds...

play fullscreen
1 / 36

Pharmacodynamics - PowerPoint PPT Presentation


  • 457 Views
  • Uploaded on

Pharmacodynamics. HuBio 543 September 6, 2007 Frank F. Vincenzi. Receptors, signal transduction, transmembrane signaling Agonist, antagonist, partial agonist, inverse agonist, multiple receptor states Intrinsic activity, efficacy, SAR Desensitization, up and down regulation.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Pharmacodynamics' - leona


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
pharmacodynamics

Pharmacodynamics

HuBio 543

September 6, 2007

Frank F. Vincenzi

learning objectives
Receptors, signal transduction, transmembrane signaling

Agonist, antagonist, partial agonist, inverse agonist, multiple receptor states

Intrinsic activity, efficacy, SAR

Desensitization, up and down regulation

Quantification of drug receptor interactions and responses

Potency

Schild equation and regression

Competitive and non-competitive antagonism

Spare receptors

Kd, EC50, pD2, pA2

Learning Objectives
drug d receptor r interaction
Drug(D) - Receptor (R) Interaction

k1

D + R

DR

k2

Kd = ([D] * [R]) / [DR] = k2/k1

Kd = dissociation constant

k1 = association rate constant

k2 = dissociation rate constant

several ways to express agonist potency or apparent affinity of agonists
Several ways to express agonist potency &/or apparent affinity of agonists

EC50 (effective concentration, 50%, M)

Kd (apparent dissociation constant, M)

pD2 (negative log of molar concentration (M)

of the drug giving a response, which

when compared to the maximum,

gives a ratio of 2) (i.e., negative log

of half maximal concentration)

the classical concentration effect relationship and the laws of mass action
The classical concentration-effect relationship and the laws of mass action

Effect = (Effectmax * conc)/(conc + EC50)

In the previous data slide EC50 ~ 3 x 10-9 M

Thus, the apparent Kd of ACh ~ 3 x 10-9 M

IF (NOTE, BIG IF)

EC50 = Kd then

Bound drug = (Bmax * conc)/(conc + Kd)

binding of a radioligand to tissue samples
Binding of a radioligand to tissue samples

Adapted fromSchaffhauser et al., 1998

scatchard analysis of binding of 125 iodocyanopindolol to beta receptors in human heart
Scatchard analysis of binding of 125iodocyanopindolol to beta-receptors in human heart

Adapted fromHeitz et al., 1983

acetylcholine ach one drug with different affinities for two different receptors
Acetylcholine (ACh): One drug with different affinities for two different receptors

(adapted from Clark, 1933)

ach different affinities for different receptors
ACh: Different affinities for different receptors
  • Muscarinic receptors
      • EC50 = apparent Kd ~ 3 x 10-8 M, pD2 ~7.5
  • Nicotinic receptor
      • EC50 = apparent Kd ~ 3 x 10-6 M, pD2 ~5.5
      • In these experiments, affinity of ACh for muscarinic receptors is apparently ~100 times greater than for nicotinic receptors. ACh is 100 times more potent as a muscarinic agonist than as a nicotinic agonist. So, when injected as a drug, muscarinic effects normally predominate, unless the muscarinic receptors are blocked. (No problem for nerves releasing ACh locally onto nicotinic receptors, however).
properties of an agonist e g ach on receptors lacking spontaneous activity
Properties of an agonist (e.g., ACh) (on receptors lacking spontaneous activity)
  • Accessibility
  • Affinity
  • Intrinsic activity > 0
different affinities of related agonist drugs for the same receptor different potencies
Different affinities of related agonist drugs for the same receptor: Different potencies

(adapted from Ariëns et al., 1964)

properties of an antagonist on receptors lacking spontaneous activity
Properties of an antagonist (on receptors lacking spontaneous activity)
  • Accessibility
  • Affinity
  • Intrinsic activity = 0
properties of a partial agonist on receptors lacking spontaneous activity
Properties of a partial agonist (on receptors lacking spontaneous activity)
  • Accessibility
  • Affinity
  • 0 < Intrinsic activity < 1
theoretical concentration effect curves for a full and partial agonist of a given receptor
Theoretical concentration-effect curves for a full and partial agonist of a given receptor
multiple receptor conformational states how to understand agonists partial agonists and antagonists
Multiple receptor conformational states:How to understand agonists, partial agonists and antagonists
simple case receptor has little or no spontaneous activity in the absence of added drug
Simple case: receptor has little or no spontaneous activity in the absence of added drug

‘inactive’ R

‘active’ R

slide21
An agonist binds more tightly to the ‘active’ state of the receptor: Equilibrium shifts to the active state
slide22
A competitive antagonist binds equally tightly to the ‘inactive’ and active states of the receptor: No change in equilibrium
slide23
A partial agonist binds to both the ‘inactive’ and ‘active’ states of the receptor: Partial shift of equilibrium
slide24

Multiple receptor states: How to understand inverse agonists(in this LESS SIMPLE case, the receptorhas spontaneous (often called constituitive) activity in the absence of added drug)

slide26
Inverse agonists bind more tightly to the resting state of the spontaneously active receptor: Equilibrium shifts toward the inactive state
how to quantify drug antagonism
How to quantify drug antagonism
  • Schild Equation
      • (C’/C) = 1 + ([I]/Ki)
  • Schild plot or Schild regression
      • log(C’/C - 1) vs. log [I]
  • pA2 = -log([I] giving a dose ratio of 2)
  • Where [I] = Kd of antagonist at its receptor.
antagonism of acetylcholine by atropine
Antagonism of acetylcholine by atropine

Adapted from Altiere et al., 1994

antagonism of acetylcholine by pirenzepine
Antagonism of acetylcholine by pirenzepine

Adapted from Altiere et al., 1994

schild plot antagonism of acetylcholine by two different antagonists
Schild plot: Antagonism of acetylcholine by two different antagonists

3

atropine

pirenzepine

2

1

0

-6

-5

-10

-9

-8

-7

log [antagonist] (M)

Adapted from Altiere et al., 1994

slide33
DifferentpA2 values (affinities)for different receptors of some clinically useful drugs:The basis of therapeutic selectivity
drug d receptor r interaction36
Drug(D) - Receptor (R) Interaction

k1

D + R

DR

k2

Kd = ([D] * [R]) / [DR] = k2/k1

Kd = dissociation constant

k1 = association rate constant

k2 = dissociation rate constant